Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation

Zhou,Dai‑Ying; Ding,Ning; Du,Zhi‑Yun; Cui,Xiao‑Xing; Wang,Hong; Wei,Xing‑Chuan; Conney,Allan  H.; Zhang,Kun; Zheng,Xi

doi:10.3892/mmr.2014.2380

Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation

Authors:
- Dai‑Ying Zhou
- Ning Ding
- Zhi‑Yun Du
- Xiao‑Xing Cui
- Hong Wang
- Xing‑Chuan Wei
- Allan H. Conney
- Kun Zhang
- Xi Zheng
View Affiliations

Affiliations: Laboratory of Natural Medicinal Chemistry & Green Chemistry, Guangdong University of Technology, Guangzhou, Guangdong 510006, P.R. China, Department of Chemical Biology, Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
Published online on: July 14, 2014 https://doi.org/10.3892/mmr.2014.2380
Pages: 1315-1322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The androgen receptor (AR) has a critical role in prostate cancer development and progression. Several curcumin analogues (A10, B10, C10, E10 and F10) with different linker groups were investigated for their effects in human prostate cancer CWR‑22Rv1 and LNCaP cell lines. The ability of these compounds to inhibit testosterone (TT)‑ or dihydrotestosterone (DHT)‑induced AR activity was determined by an AR‑linked luciferase assay and by TT‑ or DHT‑induced expression of prostate specific antigen. Compounds F10 and E10 had stronger inhibitory effects on the growth of cultured CWR‑22Rv1 and LNCaP cell lines, and they also had enhanced stimulatory effects on apoptosis compared with curcumin and other curcumin analogues (A10, B10, C10) in CWR‑22Rv1 cells. E10 and F10 were more potent inhibitors of AR activity than curcumin, A10 and B10. The higher activities of E10 and F10 may be correlated with a heteroatom linker. The results indicate that one of the potential mechanisms for the anticancer effect of the curcumin analogues was inhibition of AR pathways in human prostate cancer cells.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gao W, Bohl CE and Dalton JT: Chemistry and structural biology of androgen receptor. Chem Rev. 105:3352–3370. 2005. View Article : Google Scholar : PubMed/NCBI
3	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar
4	Klotz L: Hormone therapy for patients with prostate carcinoma. Cancer. 88(Suppl): 3009–3014. 2000. View Article : Google Scholar : PubMed/NCBI
5	Simmons MN and Klein EA: Combined androgen blockade revisited: Emerging options for the treatment of castration-resistant prostate cancer. Urology. 73:697–705. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kuttan R, Bhanumathy P, Nirmala K, et al: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 29:197–202. 1985. View Article : Google Scholar : PubMed/NCBI
7	Huang MT, Smart RC, Wong CQ, et al: Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48:5941–5946. 1988.
8	Huang MT, Wang ZY, Georgiadis CA, et al: Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene. Carcinogenesis. 13:2183–2186. 1992.
9	Huang MT, Lou YR, Ma W, et al: Inhibitory effects of dietary curcumin on forestomach duodenal, and colon carcinogenesis in mice. Cancer Res. 54:5841–5847. 1994.PubMed/NCBI
10	Rao CV, Rivenson A, Simi B, et al: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55:259–266. 1995.PubMed/NCBI
11	Leite KR, Chade DC, Sanudo A, et al: Effects of curcumin in an orthotopic murine bladder tumor model. Int Braz J Urol. 35:599–606. 2009. View Article : Google Scholar : PubMed/NCBI
12	Agrawal DK and Mishra PK: Curcumin and its analogues: potential anticancer agents. Med Res Rev. 30:818–860. 2010.PubMed/NCBI
13	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
14	Teiten MH, Gaascht F, Eifes S, et al: Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 5:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bill MA, Bakan C, Benson DM Jr, et al: Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther. 8:2726–2735. 2009. View Article : Google Scholar : PubMed/NCBI
16	Johnson SM, Gulhati P, Arrieta I, et al: Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 29:3185–3190. 2009.PubMed/NCBI
17	Piantino CB, Salvadori FA, Ayres PP, et al: An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol. 35:354–360. 2009. View Article : Google Scholar : PubMed/NCBI
18	Kuo CT, Chen BC, Yu CC, et al: Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells. J Biomed Sci. 16:432009. View Article : Google Scholar : PubMed/NCBI
19	Sahu RP, Batra S and Srivastava SK: Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
20	Thangapazham RL, Sharma A and Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 8:E443–E449. 2006. View Article : Google Scholar : PubMed/NCBI
21	Anand P, Sundaram C, Jhurani S, et al: Curcumin and cancer: an ‘old-age’ disease with an ‘age-old’ solution. Cancer Lett. 267:133–164. 2008.
22	Dhillon N, Aggarwal BB, Newman RA, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
23	Cheng AL, Hsu CH, Lin JK, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
24	Wei X, Du ZY, Zheng X, et al: Synthesis and evaluation of curcumin-related compounds for anticancer activity. Eur J Med Chem. 53:235–245. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zheng X, Chang RL, Cui XX, et al: Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res. 64:1811–1820. 2004. View Article : Google Scholar : PubMed/NCBI
26	Aggarwal BB: Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther. 7:1436–1440. 2008. View Article : Google Scholar : PubMed/NCBI
27	Nakamura K, Yasunaga Y, Segawa T, et al: Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol. 21:825–830. 2002.PubMed/NCBI
28	Tsui KH, Feng TH, Lin CM, et al: Curcumin blocks the activation of androgen and interlukin-6 on prostate specific antigen expression in human prostatic carcinoma cells. J Androl. 29:661–668. 2008. View Article : Google Scholar : PubMed/NCBI
29	Anand P, Kunnumakkara AB, Newman RA, et al: Bioavailability of curcumin: Problems and promises. Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
30	Adams BK, Ferstl EM, Davis MC, et al: Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents. Bioorg Med Chem. 12:3871–3883. 2004. View Article : Google Scholar : PubMed/NCBI
31	Basile V, Ferrari E, Lazzari S, et al: Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol. 78:1305–1315. 2009. View Article : Google Scholar : PubMed/NCBI
32	Ishida J, Ohtsu H, Tachibana Y, et al: Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem. 10:3481–3487. 2002. View Article : Google Scholar : PubMed/NCBI
33	Ohori H, Yamakoshi H, Tomizawa M, et al: Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 5:2563–2571. 2006. View Article : Google Scholar : PubMed/NCBI
34	Zhou J, Geng G, Shi Q, et al: Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem. 52:5546–5550. 2009. View Article : Google Scholar : PubMed/NCBI
35	Shi Q, Shih CC and Lee KH: Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer Agents Med Chem. 9:904–912. 2009. View Article : Google Scholar : PubMed/NCBI
36	Zsila F, Bikadi Z and Simonyi M: Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids. Org Biomol Chem. 2:2902–2910. 2004. View Article : Google Scholar
37	Caruso F, Rossi M, Benson A, et al: Ruthenium-arene complexes of curcumin: X-ray and density functional theory structure, synthesis, and spectroscopic characterization, in vitro antitumor activity, and DNA docking studies of (p-Cymene) Ru (curcuminato) chloro. J Med Chem. 55:1072–1081. 2012. View Article : Google Scholar